Comparison of the efficacy of intradermal injected tranexamic acid vs hydroquinone cream in the treatment of melasma.
hydroquinone
melasma
tranexamic acid
treatment
Journal
Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
13
3
2019
pubmed:
13
3
2019
medline:
13
3
2019
Statut:
epublish
Résumé
Melasma is a common benign acquired pigmentary dermatosis due to a disorder in the function of the melanogenesis process. Although several treatments are currently used, it remains a great challenge. The aim of this study is to compare the efficacy of intradermal injected tranexamic acid (TA) vs hydroquinone (HQ) cream in the treatment of melasma. In this prospective split face controlled clinical trial, 49 patients were randomly divided into two groups of A (24 persons) and B (25 persons). Patients received TA intradermal injections every 2 weeks on the right side of the face with a concentration of 4 mg/ mL in group A and a concentration of 10 mg/mL in group B. The left side in both groups was treated twice daily with topical 4% HQ cream, and treatment continued for 12 weeks in both groups. Melasma Area and Severity Index (MASI) scores were measured for each side of the face at baseline and at weeks 4, 8, 12, and 24. SPSS, version 22, Forty-one patients (21 in group A and 20 in group B) completed the study. The MASI score in the 12th week significantly decreased compared to the baseline for group A, group B, and HQ cream. However, no statistically significant difference was observed between the MASI score of patients in groups A and B. Also, the comparison of TA at the concentration of 4 mg/ mL compared to the 4% HQ cream showed that the MASI scores in the eighth week ( Injection of TA intradermally can be an effective treatment for melasma.
Sections du résumé
BACKGROUND
BACKGROUND
Melasma is a common benign acquired pigmentary dermatosis due to a disorder in the function of the melanogenesis process. Although several treatments are currently used, it remains a great challenge.
AIM
OBJECTIVE
The aim of this study is to compare the efficacy of intradermal injected tranexamic acid (TA) vs hydroquinone (HQ) cream in the treatment of melasma.
MATERIALS AND METHODS
METHODS
In this prospective split face controlled clinical trial, 49 patients were randomly divided into two groups of A (24 persons) and B (25 persons). Patients received TA intradermal injections every 2 weeks on the right side of the face with a concentration of 4 mg/ mL in group A and a concentration of 10 mg/mL in group B. The left side in both groups was treated twice daily with topical 4% HQ cream, and treatment continued for 12 weeks in both groups. Melasma Area and Severity Index (MASI) scores were measured for each side of the face at baseline and at weeks 4, 8, 12, and 24. SPSS, version 22,
RESULTS
RESULTS
Forty-one patients (21 in group A and 20 in group B) completed the study. The MASI score in the 12th week significantly decreased compared to the baseline for group A, group B, and HQ cream. However, no statistically significant difference was observed between the MASI score of patients in groups A and B. Also, the comparison of TA at the concentration of 4 mg/ mL compared to the 4% HQ cream showed that the MASI scores in the eighth week (
CONCLUSION
CONCLUSIONS
Injection of TA intradermally can be an effective treatment for melasma.
Identifiants
pubmed: 30858717
doi: 10.2147/CCID.S191964
pii: ccid-12-115
pmc: PMC6386353
doi:
Types de publication
Journal Article
Langues
eng
Pagination
115-122Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Dermatol Ther. 2004;17(2):151-7
pubmed: 15113282
Dermatol Surg. 2006 May;32(5):626-31
pubmed: 16706756
J Am Acad Dermatol. 2006 Dec;55(6):1048-65
pubmed: 17097400
J Dermatol Sci. 2007 May;46(2):111-6
pubmed: 17363223
Dermatol Ther. 2007 Sep-Oct;20(5):308-13
pubmed: 18045355
An Bras Dermatol. 2009 Nov-Dec;84(6):623-35
pubmed: 20191174
Eur J Dermatol. 2010 May-Jun;20(3):289-92
pubmed: 20400389
Int J Mol Sci. 2010 Jun 18;11(6):2566-75
pubmed: 20640168
J Am Acad Dermatol. 2011 Oct;65(4):699-714
pubmed: 21920242
J Eur Acad Dermatol Venereol. 2013 Aug;27(8):1035-9
pubmed: 22329442
J Eur Acad Dermatol Venereol. 2013 Jan;27 Suppl 1:19-23
pubmed: 23205541
J Cosmet Dermatol. 2013 Mar;12(1):57-66
pubmed: 23438143
J Cutan Aesthet Surg. 2013 Jul;6(3):139-43
pubmed: 24163529
Dermatol Ther (Heidelb). 2014 Dec;4(2):165-86
pubmed: 25269451
An Bras Dermatol. 2015 Mar-Apr;90(2):196-200
pubmed: 25830989
Acupunct Med. 2015 Aug;33(4):254-61
pubmed: 25900923
Indian J Dermatol. 2016 Jan-Feb;61(1):95-6
pubmed: 26955108
Am J Clin Dermatol. 2017 Jun;18(3):373-381
pubmed: 28283893
Acta Derm Venereol. 2017 Jul 6;97(7):776-781
pubmed: 28374042
Clin Exp Dermatol. 2017 Oct;42(7):728-734
pubmed: 28649780
J Dermatolog Treat. 2018 Jun;29(4):405-410
pubmed: 29027510
Clin Dermatol. 1997 Jan-Feb;15(1):35-43
pubmed: 9034654